沙库必曲/缬沙坦治疗心力衰竭研究概述

摘要

Heart failure is a leading cause of death and disability in adults.Significant advances have been made in pharmacotherapy of heart failure that effectively reduce morbidity and mortality rates.Sacubitril/valsartan is incorporated into the standard therapy for heart failure with the result of reduced ejection fraction.Through neprilysin inhibition and angiotensin Ⅱ blockade,the drug has been shown to reduce the rate of cardiovascular death and hospitalization related to heart failure,providing an improvement over current available therapies.In this article we reviewed sacubitril/valsartan,its role in regards to drug mechanism,treatment affects,adverse reactions and safety in the treatment of heart failure.%心力衰竭是成人死亡和残疾的主要原因.心力衰竭的药物治疗已经取得了重大进步,有效减少了合并症和病死率.其中药物沙库必曲/缬沙坦已被纳入射血分数减少的心力衰竭的标准疗法.该药物可以通过同时抑制脑啡肽酶和阻断血管紧张素Ⅱ受体从而减少心血管死亡和因心力衰竭住院风险,效果优于目前其他同类药物,现对该药的作用机制、治疗效果、不良反应等研究进展进行介绍.